A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

Sponsor
Jiangsu Cancer Institute & Hospital
Study ID
NCT04624893
Status
Unknown

Conditions

  • Diffuse Large B-Cell Lymphoma (DLBCL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Polatuzumab Vedotin-Piiq — DRUG
    Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.

Study Details

To assess the clinical outcomes following treatment with Pola in combination with Bendamustine, Rituximab (BR) or Rituximab (R) in patients with R/R DLBCL who are not eligible for transplantation in the real-world setting.

Key Dates

Start date
Dec 12, 2019
Status verified
Nov 2020
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
35 participants (estimated)

Arms

  • Arm: Pola BR/R
    Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.

Primary Outcome Measure

Investigator-assessed best overall response (BOR) [ Time Frame: From the start of the treatment until the date of first documented progression or the completion of the treatment(up to six cycles, each cycle is 21 days) ]

Central Contacts

Related Studies